StockNews.com started coverage on shares of Perficient (NASDAQ:PRFT – Free Report) in a research note issued to investors on Saturday morning. The firm issued a sell rating on the digital transformation consultancy’s stock.
Perficient Price Performance
Perficient stock opened at $75.96 on Friday. Perficient has a 52 week low of $42.51 and a 52 week high of $76.01. The company has a quick ratio of 4.16, a current ratio of 4.16 and a debt-to-equity ratio of 0.70. The firm’s 50-day simple moving average is $75.27 and its 200 day simple moving average is $68.87. The firm has a market capitalization of $2.67 billion, a PE ratio of 32.46, a P/E/G ratio of 1.96 and a beta of 1.64.
Perficient (NASDAQ:PRFT – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The digital transformation consultancy reported $0.79 EPS for the quarter, missing the consensus estimate of $0.80 by ($0.01). Perficient had a return on equity of 18.39% and a net margin of 8.48%. The business had revenue of $222.82 million during the quarter, compared to analysts’ expectations of $223.58 million. On average, equities research analysts predict that Perficient will post 3.21 EPS for the current fiscal year.
Institutional Investors Weigh In On Perficient
Perficient Company Profile
Perficient, Inc provides digital consultancy services and solutions in the United States and internationally. It offers strategy and transformation solutions in digital strategy, technology strategy, business velocity and growth, and organizational change management; and data and intelligence solutions in the areas of analytics, artificial intelligence and machine learning, big data, business intelligence, and custom product portfolios.
See Also
- Five stocks we like better than Perficient
- What is a Stock Market Index and How Do You Use Them?
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Best Stocks Under $5.00
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Perficient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perficient and related companies with MarketBeat.com's FREE daily email newsletter.